The global generative AI in biology market size is calculated at USD 101.82 million in 2024, grew to USD 119.43 million in 2025, and is predicted to hit around USD 502.12 million by 2034, poised to grow at a CAGR of 17.3% between 2024 and 2034. The North America generative AI in biology market size accounted for USD 39.71 million in 2024 and is anticipated to grow at the fastest CAGR of 17.45% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
5.1. COVID-19 Landscape: Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Application
8.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Application, 2024-2034
8.1.1 Drug Discovery and Development
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Medical Imaging
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Genomics and Proteomics
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Protein Engineering
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Synthetic Biology
8.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Technology
9.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Technology, 2024-2034
9.1.1. Generative Adversarial Networks
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Variational Autoencoders
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Reinforcement Learning
9.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By End-Use
10.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by End-Use, 2024-2034
10.1.1. Pharmaceutical and Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Healthcare Provider
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Research Institutions
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
Chapter 12. Company Profiles
12.1. NVIDIA Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. IBM Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BenevolentAI
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. DeepMind Technologies Limited
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Insilico Medicine
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Recursion Pharmaceuticals
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Zymergen
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample